{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T19:37:47Z","timestamp":1788550667813,"version":"build-2803163510"},"reference-count":249,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010414","name":"Health Research Board","doi-asserted-by":"publisher","award":["ILP-POR-2022-030"],"award-info":[{"award-number":["ILP-POR-2022-030"]}],"id":[{"id":"10.13039\/100010414","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010414","name":"Health Research Board","doi-asserted-by":"publisher","award":["DIFA-2023-005"],"award-info":[{"award-number":["DIFA-2023-005"]}],"id":[{"id":"10.13039\/100010414","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010414","name":"Health Research Board","doi-asserted-by":"publisher","award":["HRB KTA-2024-002"],"award-info":[{"award-number":["HRB KTA-2024-002"]}],"id":[{"id":"10.13039\/100010414","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Classical serotonergic psychedelics, such as psilocybin, show emerging evidence of therapeutic potential across a range of mental health disorders, including depression, anxiety, and substance use disorders, with indications of transdiagnostic efficacy. While early-phase studies yielded encouraging results, recent larger-scale phase 3 trials, such as those evaluating psilocybin for treatment-resistant depression, have shown more modest effects, and further findings from ongoing trials are awaited. Despite the absence of regulatory approvals from the U.S. Food and Drug Administration and European Medicines Agency, a small but growing number of countries have permitted psychedelic therapies within regulated clinical settings. Across these divergent international approaches, the long-term trajectory and real-world impact of these therapies within public health systems remain uncertain. In anticipation of potential future approval, Ireland has an opportunity to draw on international experience and proactively plan for the integration of psychedelic therapies. Building on emerging evidence, international frameworks, and Ireland-specific policy and health system features, this paper examines the challenges of integrating psychedelic therapies into the Irish public healthcare system. These challenges span regulatory approval, Health Technology Assessment, service implementation, workforce capacity, and the evaluation of long-term patient outcomes. The aim is to inform policymakers, practitioners, and researchers about key system-level considerations.<\/jats:p>","DOI":"10.1093\/ijnp\/pyag028","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T11:40:10Z","timestamp":1778326810000},"source":"Crossref","is-referenced-by-count":1,"title":["Trials, trips, and tribulations: pathways for implementing psychedelic therapy in Ireland"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9545-0615","authenticated-orcid":false,"given":"John R","family":"Kelly","sequence":"first","affiliation":[{"name":"Department of Psychiatry, School of Medicine, Trinity College Dublin , Dublin ,","place":["Ireland"]},{"name":"Trinity College Institute of Neuroscience, Trinity College Dublin ,","place":["Ireland"]},{"name":"Psychedelic Research Group, Tallaght University Hospital and Trinity College Dublin , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Sheridan","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, School of Medicine, Trinity College Dublin , Dublin ,","place":["Ireland"]},{"name":"Psychedelic Research Group, Tallaght University Hospital and Trinity College Dublin , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Iusan","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, School of Medicine, Trinity College Dublin , Dublin ,","place":["Ireland"]},{"name":"Psychedelic Research Group, Tallaght University Hospital and Trinity College Dublin , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Coakley","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, School of Medicine, Trinity College Dublin , Dublin ,","place":["Ireland"]},{"name":"Psychedelic Research Group, Tallaght University Hospital and Trinity College Dublin , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Burke","sequence":"additional","affiliation":[{"name":"Psychedelic Research Group, Tallaght University Hospital and Trinity College Dublin , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Brennan","sequence":"additional","affiliation":[{"name":"Psychedelic Research Group, Tallaght University Hospital and Trinity College Dublin , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"MacDonald","sequence":"additional","affiliation":[{"name":"Psychedelic Research Group, Tallaght University Hospital and Trinity College Dublin , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo-Hanna","family":"Ivers","sequence":"additional","affiliation":[{"name":"Psychedelic Research Group, Tallaght University Hospital and Trinity College Dublin , Dublin ,","place":["Ireland"]},{"name":"Department of Public Health and Primary Care, Trinity College Dublin , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Trepel","sequence":"additional","affiliation":[{"name":"Psychedelic Research Group, Tallaght University Hospital and Trinity College Dublin , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrath","family":"Tormey","sequence":"additional","affiliation":[{"name":"Psychedelic Research Group, Tallaght University Hospital and Trinity College Dublin , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Finnegan","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, School of Medicine, Trinity College Dublin , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth W","family":"Young","sequence":"additional","affiliation":[{"name":"Psychedelic Research Group, Tallaght University Hospital and Trinity College Dublin , Dublin ,","place":["Ireland"]},{"name":"School of Computer Science and Statistics, Trinity College Dublin , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9734-216X","authenticated-orcid":false,"given":"Andrew","family":"Harkin","sequence":"additional","affiliation":[{"name":"Trinity College Institute of Neuroscience, Trinity College Dublin ,","place":["Ireland"]},{"name":"Psychedelic Research Group, Tallaght University Hospital and Trinity College Dublin , Dublin ,","place":["Ireland"]},{"name":"School of Pharmacy & Pharmaceutical Sciences, Trinity College Dublin , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"2026060919230479100_ref1","volume-title":"OECD\/European Observatory on Health Systems and Policies (2023), Ireland: Country Health Profile 2023, State of Health in the EU","author":"OECD","year":"2023"},{"key":"2026060919230479100_ref2","doi-asserted-by":"publisher","volume-title":"Health at a Glance: Europe 2018: State of Health in the EU Cycle","author":"OECD\/EU","DOI":"10.1787\/health_glance_eur-2018-en"},{"key":"2026060919230479100_ref3","volume-title":"Annual Report on the Activities of Irish Psychiatric Units and Hospitals 2024","author":"Daly","year":"2024"},{"key":"2026060919230479100_ref4","doi-asserted-by":"crossref","first-page":"974","DOI":"10.4088\/JCP.v66n0803","article-title":"Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials","volume":"66","author":"Thase","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"2026060919230479100_ref5","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1185\/030079906X132415","article-title":"Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials","volume":"22","author":"Machado","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"2026060919230479100_ref6","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry"},{"key":"2026060919230479100_ref7","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am J Psychiatry"},{"key":"2026060919230479100_ref8","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jad.2021.12.134","article-title":"Augmentation strategies for treatment resistant major depression: a systematic review and network meta-analysis","volume":"302","author":"Nu\u00f1ez","year":"2022","journal-title":"J Affect Disord"},{"key":"2026060919230479100_ref9","doi-asserted-by":"publisher","first-page":"e0281501","DOI":"10.1371\/journal.pone.0281501","article-title":"Guidelines\u2019 recommendations for the treatment-resistant depression: a systematic review of their quality","volume":"18","author":"Gabriel","year":"2023","journal-title":"PLoS One"},{"key":"2026060919230479100_ref10","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1177\/07067437241245384","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults: R\u00e9seau canadien pour les traitements de l'humeur et de l'anxi\u00e9t\u00e9 (CANMAT) 2023: Mise \u00e0 jour des lignes directrices cliniques pour la prise en charge du trouble d\u00e9pressif majeur chez les adultes","volume":"69","author":"Lam","year":"2024","journal-title":"Can J Psychiatr"},{"key":"2026060919230479100_ref11","doi-asserted-by":"publisher","first-page":"1040217","DOI":"10.3389\/fpsyt.2022.1040217","article-title":"Therapeutic use of psilocybin: practical considerations for dosing and administration","volume":"13","author":"MacCallum","year":"2022","journal-title":"Front Psychiatry"},{"key":"2026060919230479100_ref12","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.euroneuro.2013.12.006","article-title":"Psilocybin\u2014summary of knowledge and new perspectives","volume":"24","author":"Tyl\u0161","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"key":"2026060919230479100_ref13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/s0031-6865(97)00014-9","article-title":"Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man","volume":"72","author":"Hasler","year":"1997","journal-title":"Pharm Acta Helv"},{"key":"2026060919230479100_ref14","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/1355621021000005937","article-title":"The pharmacology of psilocybin","volume":"7","author":"Passie","year":"2002","journal-title":"Addict Biol"},{"key":"2026060919230479100_ref15","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s40262-017-0540-6","article-title":"Pharmacokinetics of escalating doses of oral psilocybin in healthy adults","volume":"56","author":"Brown","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"2026060919230479100_ref16","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/s41386-019-0324-9","article-title":"Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels","volume":"44","author":"Madsen","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"2026060919230479100_ref17","doi-asserted-by":"publisher","first-page":"113612","DOI":"10.1016\/j.biopha.2022.113612","article-title":"Serotonin 5-HT(2A), 5-HT(2c) and 5-HT(1A) receptor involvement in the acute effects of psilocybin in mice. In vitro pharmacological profile and modulation of thermoregulation and head-twitch response","volume":"154","author":"Erkizia-Santamar\u00eda","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"2026060919230479100_ref18","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/s41593-023-01316-5","article-title":"Psychedelics promote plasticity by directly binding to BDNF receptor TrkB","volume":"26","author":"Moliner","year":"2023","journal-title":"Nat Neurosci"},{"key":"2026060919230479100_ref19","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1177\/02698811231179910","article-title":"Attenuation of psilocybin mushroom effects during and after SSRI\/SNRI antidepressant use","volume":"37","author":"Gukasyan","year":"2023","journal-title":"J Psychopharmacol"},{"key":"2026060919230479100_ref20","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.euroneuro.2016.01.005","article-title":"Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A\/2A agonist ergotamine on psilocybin-induced psychedelic experience","volume":"26","author":"Pokorny","year":"2016","journal-title":"Eur Neuropsychopharmacol"},{"key":"2026060919230479100_ref21","first-page":"66","article-title":"Chlorpromazine antagonism of psilocybin effect","volume":"3","author":"Keeler","year":"1967","journal-title":"Int J Neuropsychiatry"},{"key":"2026060919230479100_ref22","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","article-title":"Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action","volume":"9","author":"Vollenweider","year":"1998","journal-title":"Neuroreport"},{"key":"2026060919230479100_ref23","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00213-007-0930-9","article-title":"Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans","volume":"3","author":"Carter","year":"2007","journal-title":"Psychopharmacology"},{"key":"2026060919230479100_ref24","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial","volume":"330","author":"Raison","year":"2023","journal-title":"JAMA"},{"key":"2026060919230479100_ref25","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jad.2024.12.061","article-title":"The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression","volume":"372","author":"Goodwin","year":"2025","journal-title":"J Affect Disord"},{"key":"2026060919230479100_ref26","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N Engl J Med"},{"key":"2026060919230479100_ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2023.01.108","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression: impact on patient-reported depression severity, anxiety, function, and quality of life","volume":"327","author":"Goodwin","year":"2023","journal-title":"J Affect Disord"},{"key":"2026060919230479100_ref28","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"2026060919230479100_ref29","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1177\/0269881119897615","article-title":"Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer","volume":"34","author":"Agin-Liebes","year":"2020","journal-title":"J Psychopharmacol"},{"key":"2026060919230479100_ref30","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J Psychopharmacol"},{"key":"2026060919230479100_ref31","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J Psychopharmacol"},{"key":"2026060919230479100_ref32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"2026060919230479100_ref33","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35010","article-title":"Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder","volume":"130","author":"Agrawal","year":"2024","journal-title":"Cancer"},{"key":"2026060919230479100_ref34","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1089\/psymed.2024.0032","article-title":"Psilocybin-assisted psychotherapy for treatment-resistant depression in bipolar II disorder","volume":"3","author":"Meshkat","year":"2025","journal-title":"Psychedelic Med (New Rochelle)"},{"key":"2026060919230479100_ref35","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1001\/jamapsychiatry.2023.4685","article-title":"Single-dose synthetic psilocybin with psychotherapy for treatment-resistant bipolar type II major depressive episodes: a nonrandomized open-label trial","volume":"81","author":"Aaronson","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"2026060919230479100_ref36","doi-asserted-by":"publisher","first-page":"2698811251362390","DOI":"10.1177\/02698811251362390","article-title":"Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: a nonrandomized open-label clinical trial","author":"McGowan","year":"2025","journal-title":"J Psychopharmacol"},{"key":"2026060919230479100_ref37","doi-asserted-by":"publisher","first-page":"20451253251408280","DOI":"10.1177\/20451253251408280","article-title":"Psychedelic therapy and postpartum depression: priorities and prospects","volume":"16","author":"Thuery","year":"2026","journal-title":"Ther Adv Psychopharmacol"},{"key":"2026060919230479100_ref38","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s41386-025-02097-0","article-title":"Psilocybin therapy for mood dysfunction in Parkinson's disease: an open-label pilot trial","volume":"50","author":"Bradley","year":"2025","journal-title":"Neuropsychopharmacology"},{"key":"2026060919230479100_ref39","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J Psychopharmacol"},{"key":"2026060919230479100_ref40","doi-asserted-by":"publisher","first-page":"e260972","DOI":"10.1001\/jamanetworkopen.2026.0972","article-title":"Psilocybin or nicotine patch for smoking cessation: a pilot randomized clinical trial","volume":"9","author":"Johnson","year":"2026","journal-title":"JAMA Netw Open"},{"key":"2026060919230479100_ref41","doi-asserted-by":"publisher","first-page":"152619","DOI":"10.1016\/j.comppsych.2025.152619","article-title":"Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: a pharmacological challenge study","volume":"142","author":"Pellegrini","year":"2025","journal-title":"Compr Psychiatry"},{"key":"2026060919230479100_ref42","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.eclinm.2020.100538","article-title":"Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study","author":"Anderson","year":"2020","journal-title":"eClinicalMedicine"},{"key":"2026060919230479100_ref43","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1038\/s41591-023-02455-9","article-title":"Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study","volume":"29","author":"Peck","year":"2023","journal-title":"Nat Med"},{"key":"2026060919230479100_ref44","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.jpsychires.2023.03.031","article-title":"Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder","volume":"161","author":"Schneier","year":"2023","journal-title":"J Psychiatr Res"},{"key":"2026060919230479100_ref45","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"2026060919230479100_ref46","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1038\/s41598-024-52967-8","article-title":"Psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use disorder: an fMRI pilot study","volume":"14","author":"Pagni","year":"2024","journal-title":"Sci Rep"},{"key":"2026060919230479100_ref47","doi-asserted-by":"publisher","first-page":"122993","DOI":"10.1016\/j.jns.2024.122993","article-title":"Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial","volume":"460","author":"Schindler","year":"2024","journal-title":"J Neurol Sci"},{"key":"2026060919230479100_ref48","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1111\/head.14420","article-title":"Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: results from a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Schindler","year":"2022","journal-title":"Headache"},{"key":"2026060919230479100_ref49","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s13311-020-00962-y","article-title":"Exploratory controlled study of the migraine-suppressing effects of psilocybin","volume":"18","author":"Schindler","year":"2021","journal-title":"Neurotherapeutics"},{"key":"2026060919230479100_ref50","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.3389\/fpain.2025.1527783","article-title":"Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: an open-label pilot clinical trial","volume":"6","author":"Aday","year":"2025","journal-title":"Front Pain Res"},{"key":"2026060919230479100_ref51","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyv072","article-title":"Pharmacokinetics and concentration-effect relationship of oral LSD in humans","volume":"19","author":"Dolder","year":"2015","journal-title":"Int J Neuropsychopharmacol"},{"key":"2026060919230479100_ref52","doi-asserted-by":"publisher","first-page":"e13143","DOI":"10.1111\/adb.13143","article-title":"Repeated low doses of LSD in healthy adults: a placebo-controlled, dose-response study","volume":"27","author":"de Wit","year":"2022","journal-title":"Addict Biol"},{"key":"2026060919230479100_ref53","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1755-5949.2008.00059.x","article-title":"The pharmacology of lysergic acid diethylamide: a review","volume":"14","author":"Passie","year":"2008","journal-title":"CNS Neurosci Ther"},{"key":"2026060919230479100_ref54","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.3389\/fphar.2024.1334218","article-title":"Effects of hallucinogenic drugs on the human heart","volume":"15","author":"Neumann","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026060919230479100_ref55","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/cpt196233314","article-title":"Quantitative studies in humans on the antagonism of lysergic acid diethylamide by chlorpromazine and phenoxybenzamine","volume":"3","author":"Murphree","year":"1962","journal-title":"Clin Pharmacol Ther"},{"key":"2026060919230479100_ref56","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/0166-4328(96)00102-7","article-title":"Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium","volume":"73","author":"Bonson","year":"1996","journal-title":"Behav Brain Res"},{"key":"2026060919230479100_ref57","doi-asserted-by":"publisher","first-page":"100725","DOI":"10.1016\/j.medj.2025.100725","article-title":"Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: a randomized trial","volume":"6","author":"M\u00fcller","year":"2025","journal-title":"Med"},{"key":"2026060919230479100_ref58","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.biopsych.2022.08.025","article-title":"Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II study","volume":"93","author":"Holze","year":"2023","journal-title":"Biol Psychiatry"},{"key":"2026060919230479100_ref59","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.13481","article-title":"Single treatment with MM120 (Lysergide) in generalized anxiety disorder: a randomized clinical trial","volume":"334","author":"Robison","year":"2025","journal-title":"JAMA"},{"key":"2026060919230479100_ref60","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/nmd.0000000000000113","article-title":"Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases","volume":"202","author":"Gasser","year":"2014","journal-title":"J Nerv Ment Dis"},{"key":"2026060919230479100_ref61","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1177\/0269881112439253","article-title":"Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials","volume":"26","author":"Krebs","year":"2012","journal-title":"J Psychopharmacol"},{"key":"2026060919230479100_ref62","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s13318-023-00822-y","article-title":"Pharmacokinetics of N,N-dimethyltryptamine in humans","volume":"48","author":"Good","year":"2023","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2026060919230479100_ref63","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41398-023-02477-4","article-title":"Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants","volume":"13","author":"Vogt","year":"2023","journal-title":"Transl Psychiatry"},{"key":"2026060919230479100_ref64","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.brainresbull.2016.04.016","article-title":"Neuropharmacology of N,N-dimethyltryptamine","volume":"126","author":"Carbonaro","year":"2016","journal-title":"Brain Res Bull"},{"key":"2026060919230479100_ref65","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nature08506","article-title":"Predicting new molecular targets for known drugs","volume":"462","author":"Keiser","year":"2009","journal-title":"Nature"},{"key":"2026060919230479100_ref66","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1126\/science.1166127","article-title":"The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator","volume":"323","author":"Fontanilla","year":"2009","journal-title":"Science"},{"key":"2026060919230479100_ref67","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/02791072.1998.10399712","article-title":"Ayahuasca preparations and serotonin reuptake inhibitors: a potential combination for severe adverse interactions","volume":"30","author":"Callaway","year":"1998","journal-title":"J Psychoactive Drugs"},{"key":"2026060919230479100_ref68","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/BF00405249","article-title":"The effect of MAO inhibition on the experimental psychosis induced by dimethyltryptamin","volume":"4","author":"Sai-Hal\u00e1sz","year":"1963","journal-title":"Psychopharmacologia"},{"key":"2026060919230479100_ref69","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/0166-4328(96)00081-2","article-title":"Human psychopharmacology of N,N-dimethyltryptamine","volume":"73","author":"Strassman","year":"1995","journal-title":"Behav Brain Res"},{"key":"2026060919230479100_ref70","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1038\/s41386-022-01344-y","article-title":"Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder","volume":"47","author":"D'Souza","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"2026060919230479100_ref71","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/jnc.15587","article-title":"The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT)","volume":"162","author":"Reckweg","year":"2022","journal-title":"J Neurochem"},{"key":"2026060919230479100_ref72","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/02698811211050543","article-title":"A narrative synthesis of research with 5-MeO-DMT","volume":"36","author":"Ermakova","year":"2022","journal-title":"J Psychopharmacol"},{"key":"2026060919230479100_ref73","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1556\/2054.2020.00123","article-title":"A comparison of reactivation experiences following vaporization and intramuscular injection (IM) of synthetic 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting","volume":"4","author":"Uthaug","year":"2020","journal-title":"J Psychedelic Stud"},{"key":"2026060919230479100_ref74","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1124\/dmd.111.039107","article-title":"Nonlinear pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine in mice","volume":"39","author":"Shen","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"2026060919230479100_ref75","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2174\/138920010794233495","article-title":"Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions","volume":"11","author":"Shen","year":"2010","journal-title":"Curr Drug Metab"},{"key":"2026060919230479100_ref76","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","volume":"101","author":"Nichols","year":"2004","journal-title":"Hallucinogens Pharmacology & Therapeutics"},{"key":"2026060919230479100_ref77","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00213-011-2616-6-718","article-title":"Behavioral effects of \u03b1,\u03b1,\u03b2,\u03b2-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor","volume":"221","author":"Halberstadt","year":"2012","journal-title":"Psychopharmacology"},{"key":"2026060919230479100_ref78","doi-asserted-by":"publisher","first-page":"e106533","DOI":"10.1371\/journal.pone.0106533","article-title":"Psychedelic N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine modulate innate and adaptive inflammatory responses through the sigma-1 receptor of human monocyte-derived dendritic cells","volume":"9","author":"Szabo","year":"2014","journal-title":"PLoS One"},{"key":"2026060919230479100_ref79","doi-asserted-by":"publisher","first-page":"3482","DOI":"10.1523\/jneurosci.09-10-03482.1989","article-title":"Differentiation of 5-hydroxytryptamine2 receptor subtypes using 125I-R-(-)2,5-dimethoxy-4-iodo-phenylisopropylamine and 3H-ketanserin","volume":"9","author":"McKenna","year":"1989","journal-title":"J Neurosci"},{"key":"2026060919230479100_ref80","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1093\/jat\/29.8.838","article-title":"A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation","volume":"29","author":"Sklerov","year":"2005","journal-title":"J Anal Toxicol"},{"key":"2026060919230479100_ref81","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1081\/clt-120030949","article-title":"Monoamine oxidase inhibitor poisoning resulting from Internet misinformation on illicit substances","volume":"42","author":"Brush","year":"2004","journal-title":"J Toxicol Clin Toxicol"},{"key":"2026060919230479100_ref82","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2026.0096","article-title":"GH001 vs placebo in patients with treatment-resistant depression: a randomized clinical trial","author":"Cuba\u0142a","year":"2026","journal-title":"JAMA Psychiatry"},{"key":"2026060919230479100_ref83","doi-asserted-by":"crossref","first-page":"1133414","DOI":"10.3389\/fpsyt.2023.1133414","article-title":"A phase 1\/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression","volume":"14","author":"Reckweg","year":"2023","journal-title":"Front Psychiatry"},{"key":"2026060919230479100_ref84","volume-title":"American Society of Clinical Psychopharmacology Annual Meeting","author":"Thase","year":"2025"},{"key":"2026060919230479100_ref85","article-title":"Results of a phase 2a clinical trial of inhaled Mebufotenin (GH001) in patients with postpartum depression","volume-title":"American Society of Clinical Psychopharmacology Annual Meeting","author":"Svendsen","year":"2025"},{"key":"2026060919230479100_ref86","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41398-024-03116-2","article-title":"Acute dose-dependent effects of mescaline in a double-blind placebo-controlled study in healthy subjects","volume":"14","author":"Klaiber","year":"2024","journal-title":"Transl Psychiatry"},{"key":"2026060919230479100_ref87","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1007\/s40262-025-01544-x","article-title":"Pharmacokinetics, pharmacodynamics, and urinary recovery of oral mescaline hydrochloride in healthy participants","volume":"64","author":"Mueller","year":"2025","journal-title":"Clin Pharmacokinet"},{"key":"2026060919230479100_ref88","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1038\/s41386-023-01607-2","article-title":"Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants","volume":"48","author":"Ley","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"2026060919230479100_ref89","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.euroneuro.2016.05.001","article-title":"Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens","volume":"26","author":"Rickli","year":"2016","journal-title":"Eur Neuropsychopharmacol"},{"key":"2026060919230479100_ref90","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1097\/00005053-195808000-00004","article-title":"Psychodynamic relationships between the degree of anxiety and other clinical symptoms","volume":"127","author":"Lesse","year":"1958","journal-title":"J Nerv Ment Dis"},{"key":"2026060919230479100_ref91","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1212\/wnl.5.5.319","article-title":"Frenquel, a blocking agent against experimental LSD-25 and mescaline psychosis; preliminary note on its clinical application","volume":"5","author":"Fabing","year":"1955","journal-title":"Neurology"},{"key":"2026060919230479100_ref92","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2026.0132","article-title":"Efficacy and safety of psilocybin in treatment-resistant major depression: the EPISODE randomized clinical trial","volume":"83","author":"Mertens","year":"2026","journal-title":"JAMA Psychiatry"},{"key":"2026060919230479100_ref93","volume-title":"Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression","author":"COMPASS"},{"key":"2026060919230479100_ref94","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1146\/annurev-psych-020124-023532","article-title":"Therapeutic potential of psychedelic drugs: navigating high hopes, strong claims, weak evidence, and big money","volume":"76","author":"Humphreys","year":"2025","journal-title":"Annu Rev Psychol"},{"key":"2026060919230479100_ref95","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1186\/s12909-024-06141-3","article-title":"Expert recommendations for Germany\u2019s integration of psychedelic-assisted therapy","volume":"24","author":"Perez Rosal","year":"2024","journal-title":"BMC Med Educ"},{"key":"2026060919230479100_ref96","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1093\/tbm\/ibae053","article-title":"Moving psychedelic-assisted therapies from promising research into routine clinical practice: lessons from the field of implementation science","volume":"14","author":"Adams","year":"2024","journal-title":"Transl Behav Med"},{"key":"2026060919230479100_ref97","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1080\/09515089.2025.2532761","article-title":"Psychedelics beyond medicine: treatment, enhancement, hype, consent, and the limits of medicalization","volume":"38","author":"Caraccio","year":"2025","journal-title":"Philos Psychol"},{"key":"2026060919230479100_ref98","volume-title":"Guideline on Clinical Investigation of Medicinal Products in the Treatment of Depression","author":"EMA"},{"key":"2026060919230479100_ref99","volume-title":"Psychedelic Drugs: Considerations for Clinical Investigations","author":"FDA"},{"key":"2026060919230479100_ref100","doi-asserted-by":"publisher","first-page":"105525","DOI":"10.1016\/j.nsa.2025.105525","article-title":"Implementing psychedelic-assisted therapy: history and characteristics of the Swiss limited medical use program","volume":"4","author":"Liechti","year":"2025","journal-title":"Neuroscience Applied"},{"key":"2026060919230479100_ref101","volume-title":"Psychedelic Research Network","author":"ECNP"},{"key":"2026060919230479100_ref102","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1192\/j.eurpsy.2024.1806","article-title":"Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper","volume":"3","author":"Destoop","year":"2025","journal-title":"Eur Psychiatry"},{"key":"2026060919230479100_ref103","doi-asserted-by":"publisher","first-page":"e2414650","DOI":"10.1001\/jamanetworkopen.2024.14650","article-title":"Developing an ethics and policy framework for psychedelic clinical care: a consensus statement","volume":"7","author":"McGuire","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026060919230479100_ref104","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.3389\/fpsyg.2023.1119115","article-title":"ARC: a framework for access, reciprocity and conduct in psychedelic therapies","volume":"14","author":"Spriggs","year":"2023","journal-title":"Front Psychol"},{"key":"2026060919230479100_ref105","doi-asserted-by":"publisher","first-page":"109214","DOI":"10.1016\/j.neuropharm.2022.109214","article-title":"Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines","volume":"219","author":"Belouin","year":"2022","journal-title":"Neuropharmacology"},{"key":"2026060919230479100_ref106","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2024_533","article-title":"Ethical aspects of psychedelic-assisted treatments: an overview","volume":"68","author":"Poppe","year":"2024","journal-title":"Curr Top Behav Neurosci"},{"key":"2026060919230479100_ref107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/psymed.2024.0019","article-title":"A field-wide review and analysis of study materials used in psilocybin trials: assessment of two decades of research","volume":"3","author":"Yaden","year":"2025","journal-title":"Psychedelic Medicine"},{"key":"2026060919230479100_ref108","doi-asserted-by":"publisher","DOI":"10.1080\/23294515.2025.2526339","article-title":"Informed consent documents from psychedelic clinical trials: a descriptive ethical analysis","volume":"16","author":"Cheung","journal-title":"AJOB Empir Bioeth"},{"key":"2026060919230479100_ref109","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1080\/15265161.2024.2342764","article-title":"The Hopkins-Oxford Psychedelics Ethics (HOPE) Working Group Consensus Statement","volume":"24","author":"Jacobs","year":"2024","journal-title":"Am J Bioeth"},{"key":"2026060919230479100_ref110","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1176\/appi.ps.20220525","article-title":"Ethical and practical considerations for the use of psychedelics in psychiatry","volume":"74","author":"Barber","year":"2023","journal-title":"Psychiatr Serv (Wash DC)"},{"key":"2026060919230479100_ref111","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.3389\/fpsyt.2021.737738","article-title":"Translating psychedelic therapies from clinical trials to community clinics: building bridges and addressing potential challenges ahead","volume":"12","author":"Williams","year":"2021","journal-title":"Front Psychiatry"},{"key":"2026060919230479100_ref112","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1177\/02698811241265756-700","article-title":"A framework for assessment of adverse events occurring in psychedelic-assisted therapies","volume":"38","author":"Palitsky","year":"2024","journal-title":"J Psychopharmacol"},{"key":"2026060919230479100_ref113","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103517","article-title":"Considerations and cautions for the integration of psilocybin into routine clinical care: a consensus statement from the US National Network of Depression Centers\u2019 Task Group on Psychedelics and Related Compounds","volume":"89","author":"Hosein","year":"2025","journal-title":"eClinicalMedicine"},{"key":"2026060919230479100_ref114","doi-asserted-by":"publisher","first-page":"e254928","DOI":"10.1001\/jamahealthforum.2025.4928","article-title":"Gaps in US psychedelic policy and how to close them","volume":"6","author":"Propes","year":"2025","journal-title":"JAMA Health Forum"},{"key":"2026060919230479100_ref115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1192\/bjp.2026.10612","article-title":"Psychedelics in NHS services: exploring a model for real-world implementation of psilocybin","author":"Smith","year":"2026","journal-title":"Br J Psychiatry"},{"key":"2026060919230479100_ref116","article-title":"Guidance for coalitions informing the standardisation and implementation of psychedelic therapies in Europe","author":"Le Forsonney","year":"2026","journal-title":"PsyPal."},{"key":"2026060919230479100_ref117","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S0140-6736(23)00264-7","article-title":"The therapeutic potential of psychedelics: the European regulatory perspective","volume":"401","author":"Butlen-Ducuing","year":"2023","journal-title":"Lancet"},{"key":"2026060919230479100_ref118","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S2215-0366(24)00203-7","article-title":"Applying the EU regulatory framework for the clinical use of psychedelics","volume":"12","author":"Butlen-Ducuing","year":"2025","journal-title":"Lancet Psychiatry"},{"key":"2026060919230479100_ref119","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/add.16575","article-title":"Crafting effective regulatory policies for psychedelics: what can be learned from the case of cannabis?","volume":"120","author":"Andrews","year":"2025","journal-title":"Addiction"},{"key":"2026060919230479100_ref120","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1176\/appi.ajp.20230787","article-title":"Psychedelic regulation beyond the Controlled Substances Act: a three-dimensional framework for characterizing policy options","volume":"182","author":"Mian","year":"2025","journal-title":"Am J Psychiatry"},{"key":"2026060919230479100_ref121","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.lanepe.2025.101537","article-title":"Current perspectives on psychedelic treatments in Europe","author":"Madero","year":"2026","journal-title":"Lancet Reg Health Eur"},{"key":"2026060919230479100_ref122","doi-asserted-by":"publisher","first-page":"104242","DOI":"10.1016\/j.ajp.2024.104242","article-title":"Exploring the regulatory framework of psychedelics in the US & Europe","volume":"102","author":"Behera","year":"2024","journal-title":"Asian J Psychiatr"},{"key":"2026060919230479100_ref123","doi-asserted-by":"publisher","DOI":"10.1111\/bph.17398","article-title":"The Australia story: current status and future challenges for the clinical applications of psychedelics","author":"Nutt","year":"2024","journal-title":"Br J Pharmacol"},{"key":"2026060919230479100_ref124","article-title":"Government response to the ACMD's report on barriers to research: part 2 (accessible)","author":"Home Office ACotMoD","year":"2025"},{"key":"2026060919230479100_ref125","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(25)00277-9","article-title":"Compassionate use of psilocybin for treatment-resistant depression in Germany","volume":"13","author":"Gr\u00fcnder","year":"2025","journal-title":"Lancet Psychiatry"},{"key":"2026060919230479100_ref126","doi-asserted-by":"publisher","first-page":"e101894","DOI":"10.1136\/gpsych-2024-101894","article-title":"Expanded access to psychedelic treatments: comparing American and Canadian policies","volume":"38","author":"J\u00e9r\u00e9mie","year":"2025","journal-title":"Gen Psychiatr"},{"key":"2026060919230479100_ref127","doi-asserted-by":"publisher","DOI":"10.1038\/s44220-025-00446-y","article-title":"The promise and challenges of psychedelic-assisted therapy: lessons from Canada\u2019s special access program","volume":"3","author":"Garel","year":"2025","journal-title":"Nature Mental Health"},{"key":"2026060919230479100_ref128","doi-asserted-by":"publisher","first-page":"e70108","DOI":"10.1111\/polp.70108","article-title":"Examining the perspectives of key stakeholders on the problems, policies, and politics regarding accessing psychedelic interventions to alleviate end-of-life distress","volume":"54","author":"Kratina","year":"2026","journal-title":"Policy Polit"},{"key":"2026060919230479100_ref129","volume-title":"Regulatory Sandboxes. Policy Report Drafted by WG5\u2019s Regulatory Sandboxes Task Force","author":"EU"},{"key":"2026060919230479100_ref130","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1007\/s11845-023-03378-7","article-title":"Health technology management: the experience of a managed access approach to the reimbursement of dupilumab in Ireland","volume":"192","author":"Barrett","year":"2023","journal-title":"Ir J Med Sci"},{"key":"2026060919230479100_ref131","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s40258-024-00904-1","article-title":"Utilising health technology assessment to develop managed access protocols to facilitate drug reimbursement in Ireland","volume":"22","author":"Gorry","year":"2024","journal-title":"Appl Health Econ Health Policy"},{"key":"2026060919230479100_ref132","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s40273-021-01093-8","article-title":"The utility of a rapid review evaluation process to a national HTA Agency","volume":"40","author":"Varley","year":"2022","journal-title":"PharmacoEconomics"},{"key":"2026060919230479100_ref133","doi-asserted-by":"publisher","first-page":"89","DOI":"10.7812\/TPP\/24.171","article-title":"A review of the Food and Drug Administration pipeline and proposed California legislation on medicinal psychedelics","volume":"29","author":"RWatson","year":"2025","journal-title":"Perm J"},{"key":"2026060919230479100_ref134","volume-title":"Oregon\u2019s Psychedelic Service Centers Are Closing amid High Costs and Tough Regulation","author":"Effinger"},{"key":"2026060919230479100_ref135","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s11920-023-01446-4","article-title":"Psychedelic-assisted therapy in military and veterans healthcare systems: clinical, legal, and implementation considerations","volume":"25","author":"Wolfgang","year":"2023","journal-title":"Curr Psychiatry Rep"},{"key":"2026060919230479100_ref136","doi-asserted-by":"publisher","DOI":"10.1186\/s13034-026-01060-1","article-title":"Unusual experiences and early-onset psychosis associated to hallucinogen use in adolescents: a systematic review and meta-analysis","volume":"20","author":"Armanino-Irigaray","year":"2026","journal-title":"Child Adolesc Psychiatry Ment Health"},{"key":"2026060919230479100_ref137","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1001\/jamapsychiatry.2025.3038","article-title":"Psilocybin outside the clinic: public health challenges of increasing publicity, accessibility, and use","volume":"83","author":"Hutchison","year":"2026","journal-title":"JAMA Psychiatry"},{"key":"2026060919230479100_ref138","doi-asserted-by":"publisher","first-page":"e2552505","DOI":"10.1001\/jamanetworkopen.2025.52505","article-title":"Reported safety practices of publicly advertised psychedelic retreats","volume":"9","author":"McGuire","year":"2026","journal-title":"JAMA Netw Open"},{"key":"2026060919230479100_ref139","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1001\/jamapsychiatry.2024.3532","article-title":"Emergency department visits involving hallucinogen use and risk of schizophrenia spectrum disorder","volume":"82","author":"Myran","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"2026060919230479100_ref140","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12888-024-06303-z","article-title":"Prolonged adverse effects from repeated psilocybin use in an underground psychedelic therapy training program: a case report","volume":"25","author":"Perna","year":"2025","journal-title":"BMC Psychiatry"},{"key":"2026060919230479100_ref141","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/jama.2026.1952","article-title":"Psilocybin trends in states that decriminalized use","volume":"335","author":"Black","year":"2026","journal-title":"JAMA"},{"key":"2026060919230479100_ref142","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462326103717","article-title":"Unveiling trends: insights into medicines reimbursement recommendations and health technology management in Ireland (2018\u20132023)","volume":"42","author":"Aluga","year":"2026","journal-title":"Int J Technol Assess Health Care"},{"key":"2026060919230479100_ref143","volume-title":"National Centre for Pharmacoeconomics, Ireland, Overview of the Drug Reimbursement Process","author":"NCPE"},{"key":"2026060919230479100_ref144","volume-title":"The Case for Faster and Fairer Access to Medicines","author":"(IPHA) IPHA"},{"key":"2026060919230479100_ref145","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.euroneuro.2025.11.007","article-title":"Psychedelics: the pathway to implementation in the European healthcare systems","volume":"102","author":"Gr\u00fcnder","year":"2026","journal-title":"Eur Neuropsychopharmacol"},{"key":"2026060919230479100_ref146","volume-title":"Rapid-Acting Antidepressants Face a Slow Journey to Wider Use","author":"Wilkinson","year":"2023"},{"key":"2026060919230479100_ref147","volume-title":"Decision to Not Review NICE\u2019s Technology Appraisal Guidance for Esketamine Nasal Spray for Treatment-Resistant Depression","author":"NICE"},{"key":"2026060919230479100_ref148","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/00048674231203898","article-title":"Ensuring the affordable becomes accessible\u2013lessons from ketamine, a new treatment for severe depression","volume":"58","author":"Rodgers","year":"2024","journal-title":"Aust N Z J Psychiatry"},{"key":"2026060919230479100_ref149","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jad.2025.04.041","article-title":"Combined ketamine and psychotherapy provide no additional benefit beyond ketamine alone in treating depression or PTSD: evidence from a help-seeking sample","volume":"381","author":"Moore","year":"2025","journal-title":"J Affect Disord"},{"key":"2026060919230479100_ref150","doi-asserted-by":"publisher","first-page":"868103","DOI":"10.3389\/fpsyg.2022.868103","article-title":"Toward synergies of ketamine and psychotherapy","volume":"13","author":"Mathai","year":"2022","journal-title":"Front Psychol"},{"key":"2026060919230479100_ref151","doi-asserted-by":"publisher","first-page":"1268832","DOI":"10.3389\/fpsyt.2023.1268832","article-title":"The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression","volume":"14","author":"Garel","year":"2023","journal-title":"Front Psychiatry"},{"key":"2026060919230479100_ref152","doi-asserted-by":"publisher","first-page":"101","DOI":"10.18553\/jmcp.2025.24240","article-title":"Impact of social determinants of health on esketamine nasal spray initiation among patients with treatment-resistant depression in the United States","volume":"31","author":"Clemens","year":"2025","journal-title":"J Manag Care Spec Pharm"},{"key":"2026060919230479100_ref153","doi-asserted-by":"publisher","DOI":"10.1101\/2025.06.01.25328722","article-title":"Esketamine implementation challenges in psychiatry: a qualitative analysis of mental healthcare providers\u2019 social media commentary","volume":"2025","author":"Barnett","journal-title":"medRxiv"},{"key":"2026060919230479100_ref154","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jpsychires.2018.09.013","article-title":"Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression","volume":"106","author":"Zheng","year":"2018","journal-title":"J Psychiatr Res"},{"key":"2026060919230479100_ref155","doi-asserted-by":"publisher","first-page":"116355","DOI":"10.1016\/j.psychres.2025.116355","article-title":"Demographic and clinical predictors of response and remission in the treatment of major depressive disorder with ketamine and esketamine: a systematic review","volume":"345","author":"Lima Constantino","year":"2025","journal-title":"Psychiatry Res"},{"key":"2026060919230479100_ref156","doi-asserted-by":"publisher","first-page":"1025726","DOI":"10.3389\/fpsyt.2022.1025726","article-title":"The economics of psychedelic-assisted therapies: a research agenda","volume":"13","author":"Marseille","year":"2022","journal-title":"Front Psychiatry"},{"key":"2026060919230479100_ref157","doi-asserted-by":"publisher","first-page":"7619","DOI":"10.1017\/S0033291723001411","article-title":"Cost-effectiveness of psilocybin-assisted therapy for severe depression: exploratory findings from a decision analytic model","volume":"53","author":"McCrone","year":"2023","journal-title":"Psychol Med"},{"key":"2026060919230479100_ref158","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.24m15449","article-title":"Results from a long-term observational follow-up study of a single dose of psilocybin for a treatment-resistant episode of major depressive disorder","volume":"86","author":"Goodwin","year":"2025","journal-title":"J Clin Psychiatry"},{"key":"2026060919230479100_ref159","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/s41398-025-03556-4","article-title":"Psilocybin-assisted therapy for treatment-resistant depression in the US: a model-based cost-effectiveness analysis","volume":"15","author":"Avance\u00f1a","year":"2025","journal-title":"Transl Psychiatry"},{"key":"2026060919230479100_ref160","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s41669-021-00289-0","article-title":"Revision of Ireland\u2019s cost-effectiveness threshold: new state-industry drug pricing deal should adequately reflect opportunity costs","volume":"5","author":"O'Mahony","year":"2021","journal-title":"Pharmacoecon Open"},{"key":"2026060919230479100_ref161","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/bmb\/ldq033","article-title":"Health outcomes in economic evaluation: the QALY and utilities","volume":"96","author":"Whitehead","year":"2010","journal-title":"Br Med Bull"},{"key":"2026060919230479100_ref162","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1177\/00048674221081763","article-title":"The challenges ahead for psychedelic \u2018medicine\u2019","volume":"56","author":"Muthukumaraswamy","year":"2022","journal-title":"Aust N Z J Psychiatry"},{"key":"2026060919230479100_ref163","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1089\/psymed.2023.0013","article-title":"Psychedelic commercialization: a wide-spanning overview of the emerging psychedelic industry","volume":"1","author":"Aday","year":"2023","journal-title":"Psychedelic Med (New Rochelle)"},{"key":"2026060919230479100_ref164","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1001\/jamapsychiatry.2021.3972","article-title":"The rapid rise in investment in psychedelics-cart before the horse","volume":"79","author":"Phelps","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"2026060919230479100_ref165","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/phe\/phae002","article-title":"Psychedelics in PERIL: the commercial determinants of health, financial entanglements and population health ethics","volume":"17","author":"Buchman","year":"2024","journal-title":"Public Health Ethics"},{"key":"2026060919230479100_ref166","article-title":"Patents on psychedelics: the next legal battlefront of drug development","author":"Marks","year":"2022","journal-title":"Harvard Law Review Forum"},{"key":"2026060919230479100_ref167","volume-title":"Ireland Continues to Lag Peer European Countries in Attracting Clinical Trials, According to IPHA","author":"IPHA","year":"2024"},{"key":"2026060919230479100_ref168","doi-asserted-by":"publisher","first-page":"1293243","DOI":"10.3389\/fpsyt.2023.1293243","article-title":"Group psychedelic therapy: empirical estimates of cost-savings and improved access","volume":"14","author":"Marseille","year":"2023","journal-title":"Front Psychiatry"},{"key":"2026060919230479100_ref169","doi-asserted-by":"publisher","first-page":"e0263252","DOI":"10.1371\/journal.pone.0263252","article-title":"Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the United States: findings from a phase 3 trial","volume":"17","author":"Marseille","year":"2022","journal-title":"PLoS One"},{"key":"2026060919230479100_ref170","doi-asserted-by":"publisher","first-page":"100002","DOI":"10.1016\/j.psyche.2025.100002","article-title":"Inappropriate comparator and high pricing in MDMA-assisted therapy for PTSD: a critique of the Lykos cost-effectiveness analysis","volume":"2","author":"Marseille","year":"2025","journal-title":"Psychedelics"},{"key":"2026060919230479100_ref171","volume-title":"Digital for Care","author":"HSE","year":"2025"},{"key":"2026060919230479100_ref172","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s40596-014-0050-x","article-title":"Interventional psychiatry: how should psychiatric educators incorporate neuromodulation into training?","volume":"38","author":"Williams","year":"2014","journal-title":"Acad Psychiatry"},{"key":"2026060919230479100_ref173","article-title":"The administration of electro-convulsive therapy in approved centres","volume":"2024","author":"Commission MH","year":"2023","journal-title":"Activity Report"},{"key":"2026060919230479100_ref174","doi-asserted-by":"publisher","first-page":"S303","DOI":"10.1192\/bjo.2025.10731","article-title":"Acute outpatient ECT for depression: case series of the first clinical pilot in Ireland","volume":"11","author":"Inam","year":"2025","journal-title":"BJPsych Open"},{"key":"2026060919230479100_ref175","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1192\/bjp.2021.37","article-title":"Electroconvulsive therapy for depression: 80 years of progress","volume":"219","author":"Kirov","year":"2021","journal-title":"Br J Psychiatry"},{"key":"2026060919230479100_ref176","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1176\/appi.ajp.2015.15030372","article-title":"Bitemporal versus high-dose unilateral twice-weekly electroconvulsive therapy for depression (EFFECT-Dep): a pragmatic, randomized, non-inferiority trial","volume":"173","author":"Semkovska","year":"2016","journal-title":"Am J Psychiatry"},{"key":"2026060919230479100_ref177","doi-asserted-by":"crossref","DOI":"10.1097\/YCT.0000000000000804","article-title":"Decision-making capacity for treatment after electroconvulsive therapy for depression","volume":"38","author":"Loughran","year":"2022","journal-title":"J ECT"},{"key":"2026060919230479100_ref178","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s00406-021-01294-4","article-title":"PBMC telomerase activity in depression and the response to electroconvulsive therapy","volume":"271","author":"Ryan","year":"2021","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"2026060919230479100_ref179","doi-asserted-by":"publisher","first-page":"90","DOI":"10.12688\/hrbopenres.13182.2","article-title":"Ketamine as an adjunctive therapy for major depression - a randomised controlled pragmatic pilot trial (Karma-Dep Trial)","volume":"3","author":"Gallagher","year":"2020","journal-title":"HRB Open Res"},{"key":"2026060919230479100_ref180","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/yct.0000000000000560","article-title":"Ketamine versus midazolam for depression relapse prevention following successful electroconvulsive therapy: a randomized controlled pilot trial","volume":"35","author":"Finnegan","year":"2019","journal-title":"J ECT"},{"key":"2026060919230479100_ref181","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta11240","article-title":"The clinical effectiveness and cost of repetitive transcranial magnetic stimulation versus electroconvulsive therapy in severe depression: a multicentre pragmatic randomised controlled trial and economic analysis","volume":"11","author":"McLoughlin","year":"2007","journal-title":"Health Technol Assess"},{"key":"2026060919230479100_ref182","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jad.2008.01.001","article-title":"Cost-effectiveness of transcranial magnetic stimulation vs. electroconvulsive therapy for severe depression: a multi-centre randomised controlled trial","volume":"109","author":"Knapp","year":"2008","journal-title":"J Affect Disord"},{"key":"2026060919230479100_ref183","doi-asserted-by":"publisher","first-page":"e110","DOI":"10.1017\/s0033291725000807","article-title":"Why is electroconvulsive therapy for depression more effective in older age? A causal mediation analysis","volume":"55","author":"Jelovac","year":"2025","journal-title":"Psychol Med"},{"key":"2026060919230479100_ref184","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2026.01.007","article-title":"Blunted psychedelic drug effects in older adults","volume":"34","author":"Aday","year":"2026","journal-title":"Am J Geriatr Psychiatry"},{"key":"2026060919230479100_ref185","doi-asserted-by":"crossref","DOI":"10.1097\/YCT.0000000000000945","article-title":"Personality difficulties as a predictor of electroconvulsive therapy response in depression","volume":"39","author":"Finnegan","year":"2023","journal-title":"J ECT"},{"key":"2026060919230479100_ref186","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/02698811241232548","article-title":"Psychiatric risks for worsened mental health after psychedelic use","volume":"38","author":"Marrocu","year":"2024","journal-title":"J Psychopharmacol"},{"key":"2026060919230479100_ref187","volume-title":"Australian Interventional Pharmacotherapy and Psychedelic Assisted Psychotherapy Research Registry (AIPPAP-RR)","author":"University AN"},{"key":"2026060919230479100_ref188","doi-asserted-by":"publisher","first-page":"788155","DOI":"10.3389\/fphar.2021.788155","article-title":"Therapeutic alliance and rapport modulate responses to psilocybin assisted therapy for depression","volume":"12","author":"Murphy","year":"2021","journal-title":"Front Pharmacol"},{"key":"2026060919230479100_ref189","doi-asserted-by":"publisher","first-page":"e0300501","DOI":"10.1371\/journal.pone.0300501","article-title":"The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder","volume":"19","author":"Levin","year":"2024","journal-title":"PLoS One"},{"key":"2026060919230479100_ref190","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1089\/psymed.2023.0020","article-title":"The therapeutic alliance in psychedelic-assisted psychotherapy: a novel target for research and interventions","volume":"2023","author":"Kamilar-Britt","journal-title":"Psychedelic Med (New Rochelle)"},{"key":"2026060919230479100_ref191","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1159\/000546270","article-title":"In psychedelic-assisted therapy, the alliance in the psychotherapy component is as important as the drug","volume":"94","author":"Fl\u00fcckiger","year":"2025","journal-title":"Psychother Psychosom"},{"key":"2026060919230479100_ref192","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20221043","article-title":"Must psilocybin always \u201cassist psychotherapy\u201d?","volume":"181","author":"Goodwin","year":"2023","journal-title":"Am J Psychiatry"},{"key":"2026060919230479100_ref193","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1176\/appi.ajp.20230661","article-title":"Misinterpretations and omissions: a critical response to Goodwin and colleagues\u2019 commentary on psilocybin-assisted therapy","volume":"181","author":"O'Donnell","year":"2024","journal-title":"Am J Psychiatry"},{"key":"2026060919230479100_ref194","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1176\/appi.ajp.20230905","article-title":"Psychological support for psilocybin treatment: reply to letters on our commentary","volume":"181","author":"Goodwin","year":"2024","journal-title":"Am J Psychiatry"},{"key":"2026060919230479100_ref195","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fpsyt.2020.00005","article-title":"Learning to let go: a cognitive-behavioral model of how psychedelic therapy promotes acceptance","volume":"11","author":"Wolff","year":"2020","journal-title":"Front Psychiatry"},{"key":"2026060919230479100_ref196","doi-asserted-by":"publisher","first-page":"e2554843","DOI":"10.1001\/jamanetworkopen.2025.54843","article-title":"Psychological therapy quantity and depressive symptom reduction in psychedelic-assisted therapy: a systematic review and meta-analysis","volume":"9","author":"Florineth","year":"2026","journal-title":"JAMA Netw Open"},{"key":"2026060919230479100_ref197","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.genhosppsych.2025.07.020","article-title":"A dose of therapy with psilocybin - a meta-analysis of the relationship between the amount of therapy hours and treatment outcomes in psychedelic-assisted therapy","volume":"96","author":"Hultgren","year":"2025","journal-title":"Gen Hosp Psychiatry"},{"key":"2026060919230479100_ref198","doi-asserted-by":"publisher","first-page":"119952","DOI":"10.1016\/j.jad.2025.119952","article-title":"Mapping psilocybin therapy: a systematic review of therapeutic frameworks, adaptations, and standardization across contemporary clinical trials","volume":"391","author":"Kittur","year":"2025","journal-title":"J Affect Disord"},{"key":"2026060919230479100_ref199","doi-asserted-by":"publisher","first-page":"121662","DOI":"10.1016\/j.jad.2026.121662","article-title":"The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: a post hoc path analysis","volume":"406","author":"Goodwin","year":"2026","journal-title":"J Affect Disord"},{"key":"2026060919230479100_ref200","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.genhosppsych.2025.09.003","article-title":"Key competencies for psychedelic treatment in real-world mental health care settings","volume":"97","author":"Wolff","year":"2025","journal-title":"Gen Hosp Psychiatry"},{"key":"2026060919230479100_ref201","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s12909-025-06871-y","article-title":"Further education in psychedelic-assisted therapy - experiences from Switzerland","volume":"25","author":"Aicher","year":"2025","journal-title":"BMC Med Educ"},{"key":"2026060919230479100_ref202","volume-title":"Psychotherapy Assisted by Psychedelic and Related Substances (PARS): Guidance for Psychiatrists Taking Part in Approved Research Trials","author":"Psychiatrists RCo"},{"key":"2026060919230479100_ref203","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-021-02668-2","article-title":"Psychedelic perceptions: mental health service user attitudes to psilocybin therapy","volume":"191","author":"Corrigan","year":"2021","journal-title":"Ir J Med Sci"},{"key":"2026060919230479100_ref204","volume-title":"Irish Doctors for Psychedelic Assisted Therapy Joins as the Latest Community Supporter","author":"PAREA","year":"2025"},{"key":"2026060919230479100_ref205","doi-asserted-by":"publisher","DOI":"10.1017\/ipm.2024.49","article-title":"Amid magic and menace: psychiatrists\u2019 attitudes to psilocybin therapy","volume":"41","author":"Gribben","year":"2024","journal-title":"Ir J Psychol Med"},{"key":"2026060919230479100_ref206","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1556\/2054.2024.00337","article-title":"A double-edged sword: insights from practitioners on the short and long-term negative effects of psilocybin-assisted psychological interventions","volume":"8","author":"Nordin","year":"2024","journal-title":"J Psychedelic Stud"},{"key":"2026060919230479100_ref207","doi-asserted-by":"publisher","first-page":"104938","DOI":"10.1016\/j.drugpo.2025.104938","article-title":"Building standards of psychedelic care: qualitative examination of expert perspectives on safety, inclusion, and accountability","volume":"147","author":"Chwyl","year":"2025","journal-title":"Int J Drug Policy"},{"key":"2026060919230479100_ref208","doi-asserted-by":"publisher","first-page":"727496","DOI":"10.3389\/fpsyt.2021.727496","article-title":"Co-design of guidance for patient and public involvement in psychedelic research","volume":"12","author":"Close","year":"2021","journal-title":"Front Psychiatry"},{"key":"2026060919230479100_ref209","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N Engl J Med"},{"key":"2026060919230479100_ref210","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.4809","article-title":"Psychedelic therapy vs antidepressants for the treatment of depression under equal unblinding conditions: a systematic review and meta-analysis","volume":"83","author":"Williams","year":"2026","journal-title":"JAMA Psychiatry"},{"key":"2026060919230479100_ref211","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00213-024-06722-6","article-title":"Practical considerations in the establishment of psychedelic research programs","volume":"242","author":"Barnett","year":"2025","journal-title":"Psychopharmacology"},{"key":"2026060919230479100_ref212","volume-title":"Psychedelic Research Group, TCD and TUH"},{"key":"2026060919230479100_ref213","doi-asserted-by":"publisher","first-page":"106657","DOI":"10.1016\/j.neubiorev.2026.106657","article-title":"How to set up a psychedelic study: unique considerations for research involving human participants","volume":"186","author":"Glennon","year":"2026","journal-title":"Neurosci Biobehav Rev"},{"key":"2026060919230479100_ref214","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00213-013-3024-x","article-title":"Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism","volume":"228","author":"Gigliucci","year":"2013","journal-title":"Psychopharmacology"},{"key":"2026060919230479100_ref215","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1017\/neu.2024.34","article-title":"Gene expression of kynurenine pathway enzymes in depression and following electroconvulsive therapy","volume":"37","author":"Ryan","year":"2025","journal-title":"Acta Neuropsychiatr"},{"key":"2026060919230479100_ref216","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2018.08.021","article-title":"The hippocampus in depression: more than the sum of its parts? Advanced hippocampal substructure segmentation in depression","volume":"85","author":"Roddy","year":"2018","journal-title":"Biol Psychiatry"},{"key":"2026060919230479100_ref217","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.psychres.2018.04.064","article-title":"DNA methylation differences at the glucocorticoid receptor gene in depression are related to functional alterations in hypothalamic\u2013pituitary\u2013adrenal axis activity and to early life emotional abuse","volume":"265","author":"Farrell","year":"2018","journal-title":"Psychiatry Res"},{"key":"2026060919230479100_ref218","doi-asserted-by":"publisher","first-page":"102781","DOI":"10.1016\/j.nicl.2021.102781","article-title":"Amygdala substructure volumes in major depressive disorder","volume":"31","author":"Roddy","year":"2021","journal-title":"Neuroimage Clin"},{"key":"2026060919230479100_ref219","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.psyneuen.2018.05.019","article-title":"Altered tryptophan catabolite concentrations in major depressive disorder and associated changes in hippocampal subfield volumes","volume":"95","author":"Doolin","year":"2018","journal-title":"Psychoneuroendocrinology"},{"key":"2026060919230479100_ref220","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1001\/jamapsychiatry.2025.3019","article-title":"Serial ketamine infusions as adjunctive therapy to inpatient care for depression: the KARMA-Dep 2 randomized clinical trial","volume":"82","author":"Jelovac","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"2026060919230479100_ref221","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2026.0255","article-title":"Blinding integrity in psychedelic randomized clinical trials: a systematic review","author":"Orsini","year":"2026","journal-title":"JAMA Psychiatry"},{"key":"2026060919230479100_ref222","doi-asserted-by":"publisher","DOI":"10.1038\/s44220-026-00630-8","article-title":"A living systematic review, meta-analysis and open-data resource of randomized controlled trials of psilocybin treatment for symptoms of depression","volume":"4","author":"Singleton","year":"2026","journal-title":"Nature Mental Health"},{"key":"2026060919230479100_ref223","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3389\/fphar.2018.00330","article-title":"Hypothesis: the psychedelic ayahuasca heals traumatic memories via a sigma 1 receptor-mediated epigenetic-mnemonic process","volume":"9","author":"Inserra","year":"2018","journal-title":"Front Pharmacol"},{"key":"2026060919230479100_ref224","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41398-024-03055-y","article-title":"Epigenetic mechanisms of rapid-acting antidepressants","volume":"14","author":"Inserra","year":"2024","journal-title":"Transl Psychiatry"},{"key":"2026060919230479100_ref225","doi-asserted-by":"publisher","first-page":"687615","DOI":"10.3389\/fpsyt.2021.687615","article-title":"Ceremonial ayahuasca in Amazonian retreats-mental health and epigenetic outcomes from a six-month naturalistic study","volume":"12","author":"Ruffell","year":"2021","journal-title":"Front Psychiatry"},{"key":"2026060919230479100_ref226","doi-asserted-by":"publisher","first-page":"17690","DOI":"10.1038\/s41598-021-96736-3","article-title":"LSD-stimulated behaviors in mice require \u03b2-arrestin 2 but not \u03b2-arrestin 1","volume":"11","author":"Rodriguiz","year":"2021","journal-title":"Sci Rep"},{"key":"2026060919230479100_ref227","doi-asserted-by":"publisher","author":"Rodriguiz","year":"2021","DOI":"10.1101\/2021.02.04.429772"},{"key":"2026060919230479100_ref228","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.1021\/acschemneuro.5c00667","article-title":"Zalsupindole is a nondissociative, nonhallucinogenic neuroplastogen with therapeutic effects comparable to ketamine and psychedelics","volume":"16","author":"Agrawal","year":"2025","journal-title":"ACS Chem Neurosci"},{"key":"2026060919230479100_ref229","volume-title":"Delix Therapeutics Announces Positive Efficacy Data for DLX-001 (Zalsupindole) and FDA Clearance of Phase II Trial Design Featuring At-Home Administration","author":"B"},{"key":"2026060919230479100_ref230","doi-asserted-by":"publisher","author":"Lu","year":"2025","DOI":"10.1101\/2025.04.08.647810"},{"key":"2026060919230479100_ref231","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1017\/neu.2025.10030","article-title":"Narrating the psychoneuroimmunomodulatory properties of serotonin 5-HT2A receptor psychedelics from a transdiagnostic perspective","volume":"37","author":"Thuery","year":"2025","journal-title":"Acta Neuropsychiatr"},{"key":"2026060919230479100_ref232","doi-asserted-by":"publisher","first-page":"45393","DOI":"10.1038\/s41598-025-29642-7","article-title":"A comparative assessment of the antidepressant efficacy of ketamine, psilocybin, and fluoxetine in a chronic stress model","volume":"15","author":"Dom\u017calska","year":"2025","journal-title":"Sci Rep"},{"key":"2026060919230479100_ref233","doi-asserted-by":"publisher","first-page":"100349","DOI":"10.1016\/j.ijchp.2022.100349","article-title":"Seeking the psilocybiome: psychedelics meet the microbiota-gut-brain axis","volume":"23","author":"Kelly","year":"2023","journal-title":"Int J Clin Health Psychol"},{"key":"2026060919230479100_ref234","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2025.06.012","article-title":"The polypharmacology of psychedelics reveals multiple targets for potential therapeutics","volume":"113","author":"Jain","year":"2025","journal-title":"Neuron"},{"key":"2026060919230479100_ref235","doi-asserted-by":"publisher","first-page":"800072","DOI":"10.3389\/fpsyt.2021.800072","article-title":"Psychedelic therapy\u2019s transdiagnostic effects: a research domain criteria (RDoC) perspective","volume":"12","author":"Kelly","year":"2021","journal-title":"Front Psychiatry"},{"key":"2026060919230479100_ref236","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1176\/appi.prcp.20240128","volume-title":"On Minimizing Risk and Harm in the Use of Psychedelics","author":"Evans","year":"2025"},{"key":"2026060919230479100_ref237","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41586-024-07805-2","article-title":"Frontostriatal salience network expansion in individuals in depression","volume":"633","author":"Lynch","year":"2024","journal-title":"Nature"},{"key":"2026060919230479100_ref238","doi-asserted-by":"publisher","first-page":"e257803","DOI":"10.1001\/jamanetworkopen.2025.7803","article-title":"Negative affect circuit subtypes and neural, behavioral, and affective responses to MDMA: a randomized clinical trial","volume":"8","author":"Zhang","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026060919230479100_ref239","doi-asserted-by":"publisher","first-page":"46421","DOI":"10.1038\/srep46421","article-title":"Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin","volume":"7","author":"Schartner","year":"2017","journal-title":"Sci Rep"},{"key":"2026060919230479100_ref240","doi-asserted-by":"publisher","first-page":"944753","DOI":"10.3389\/fdgth.2022.944753","article-title":"Neuroscience from the comfort of your home: repeated, self-administered wireless dry EEG measures brain function with high fidelity","volume":"4","author":"Barbey","year":"2022","journal-title":"Front Digit Health"},{"key":"2026060919230479100_ref241","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.0206","article-title":"Should inflammation be a specifier for major depression in the DSM-6?","volume":"82","author":"Jha","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"2026060919230479100_ref242","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s00213-023-06432-5","article-title":"Psilocybin therapy for treatment resistant depression: prediction of clinical outcome by natural language processing","volume":"242","author":"Dougherty","year":"2025","journal-title":"Psychopharmacology"},{"key":"2026060919230479100_ref243","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04287-9","article-title":"An international mega-analysis of psychedelic drug effects on brain circuit function","volume":"32","author":"Girn","year":"2026","journal-title":"Nat Med"},{"key":"2026060919230479100_ref244","doi-asserted-by":"publisher","first-page":"e2524119","DOI":"10.1001\/jamanetworkopen.2025.24119","article-title":"Control group outcomes in trials of psilocybin, SSRIs, or esketamine for depression: a meta-analysis","volume":"8","author":"Hieronymus","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026060919230479100_ref245","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa2302399","article-title":"Ketamine versus ECT for nonpsychotic treatment-resistant major depression","volume":"388","author":"Anand","year":"2023","journal-title":"N Engl J Med"},{"key":"2026060919230479100_ref246","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/s44220-024-00271-9","article-title":"A cognitive neural circuit biotype of depression showing functional and behavioral improvement after transcranial magnetic stimulation in the B-SMART-fMRI trial","volume":"2","author":"Tozzi","year":"2024","journal-title":"Nature Mental Health"},{"key":"2026060919230479100_ref247","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-025-03070-5","article-title":"Precision psychiatry roadmap: towards a biology-informed framework for mental disorders","volume":"30","author":"Kas","year":"2025","journal-title":"Mol Psychiatry"},{"key":"2026060919230479100_ref248","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1038\/s41386-023-01648-7","article-title":"Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication","volume":"48","author":"Goodwin","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"2026060919230479100_ref249","volume-title":"National Mental Health Research Strategy","author":"HRB","year":"2024"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyag028\/68267846\/pyag028.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/29\/6\/pyag028\/68267846\/pyag028.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/29\/6\/pyag028\/68267846\/pyag028.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T23:23:14Z","timestamp":1781047394000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/doi\/10.1093\/ijnp\/pyag028\/8675869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":249,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyag028","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,11]]},"article-number":"pyag028"}}